Lupin launches generic injection in US with 180-day exclusivity

The company has launched Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, single-dose vials

Drug maker Lupin on Friday said it has launched a generic medication to treat schizophrenia in the US with 180 days of exclusivity.

The company has launched Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, single-dose vials, with 180-day CGT exclusivity in the US, the Mumbai-based drug maker said in a statement.

This follows the recent approval received from the US Food and Drug Administration (USFDA).

This is the company’s first product using proprietary technology from Precision Sphere, the Long-acting Injectable (LAI) platform developed by its subsidiary Nanomi BV.

Risperidone for extended-release injectable suspension is bioequivalent and therapeutically equivalent to the reference listed drug Risperdal Consta LAI.

It is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults.

As per IQVIA MAT September 2025 data, Risperidone for extended-release injectable suspension has estimated sales of USD 187 million combined for 25 mg, 37.5 mg and 50 mg in the US.

“It highlights our commitment to expanding our portfolio of differentiated, complex products, marking a significant step forward in our pursuit of developing novel long-acting injectables across diverse therapeutic areas,” Lupin President US Generics Spiro Gavaris stated.

Shares of the drug maker were trading 0.37 per cent down at Rs 2,045.40 apiece on BSE.

Related Posts

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

MEERUT/SHIMLA: An illegal pharmaceutical factory allegedly manufacturing counterfeit medicines used to treat epilepsy, diabetes, typhoid and other ailments using substances such as chalk and lactose was busted in Himachal Pradesh’s…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital